A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

For years, U.S. vaccine experts have issued a universal recommendation for Covid vaccines. That could change soon.

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

and comprehensive preparedness," by focusing on "in-house development" of vaccines instead of projects from outside researchers. It is also planning to develop other vaccines for COVID-19 using ...

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that ...